Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2022-09-09
Target enrollment:
Participant gender:
Summary
Retagliptin phosphate tablet is a DPP IV inhibitor durg，study number is HR-SP2086-304. The
primary purpose of the study is to evaluate the efficacy of the combination of Retagliptin
phosphate and metformin compared with placebo and metformin in type 2 diabetes subjects with
poor glycemic control treated with metformin for 16 weeks.